XCN-010
Multiple cancers (e.g., breast, lung, prostate, ovarian, lymphoma)
Pre-clinicalActive
Key Facts
Indication
Multiple cancers (e.g., breast, lung, prostate, ovarian, lymphoma)
Phase
Pre-clinical
Status
Active
Company
About Xiconic Pharmaceuticals
Xiconic Pharmaceuticals is a private, preclinical-stage biotech developing a novel ADC targeting activated matriptase (actM), a protease overexpressed on tumor cells. Founded to commercialize discoveries from Dr. Joseph Bertino, the company's lead candidate, XCN-010, has shown broad tumor-targeting potential in preclinical models. Led by a seasoned management team with vaccine and oncology experience, Xiconic aims to translate its unique tumor-antigen targeting approach into a clinical-stage asset for multiple cancer indications.
View full company profile